{
    "root": "30016f5a-e0be-553a-e063-6394a90a5ed6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lithium Carbonate",
    "value": "20250310",
    "ingredients": [
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "LITHIUM CARBONATE",
            "code": "2BMD2GNA4V"
        }
    ],
    "indications": "Lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar I disorder:\n                  \n                     Treatment of acute manic and mixed episodes in patients 7 years and older \n        \n  \n   [see Clinical Studies (\n         \n   \n    \n                              14\n                           )]\n        \n  \n   \n                     \n                     Maintenance treatment in patients 7 years and older \n        \n  \n   [see Clinical Studies (\n         \n   \n    \n                              14\n                           )]",
    "contraindications": "Recommended starting dosage for adults and pediatric patients over 30 kg ( 2.2 ): Tablets or Capsules: 300 mg, three times daily, or Oral Solution: 8mEq lithium (5 mL) three times daily Recommended starting dosage for pediatric patients 20 to 30 kg ( 2.2 ): Tablets or Capsules: 300 mg twice daily, or Oral Solution: 8mEq (5mL), twice daily Obtain serum lithium concentration assay after 3 days, drawn 12 hours after the last oral dose and regularly until patient is stabilized. Acute Manic or Mixed Episodes (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1.2 mEq/L ( 2.2 ). Maintenance Treatment for Bipolar I Disorder (patients 7 years and older): Titrate to serum lithium concentrations 0.8 to 1 mEq/L ( 2.2 ). Pre-treatment Screening: Evaluate renal function, vital signs, electrolytes, thyroid function, concurrent medications, and pregnancy status ( 2.1 ). Mild to Moderate Renal Impairment (CLer 30 to 89 mL/min): Start with dosages less than those for patients with normal renal function, titrate slowly with frequent monitoring ( 2.5 ). Severe Renal Impairment (CLer<30mL/min): Avoid use of lithium ( 2.5 ).",
    "warningsAndPrecautions": "Lithium Carbonate Capsules USP\n                  600 mg supplied as gelatin capsules having opaque, light pink-colored caps with white bodies, imprinted with product identification “54 702” on both caps and bodies and containing a white powder.\n                  NDC: 70518-2345-00\n                  NDC: 70518-2345-01\n                  NDC: 70518-2345-02\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Storage\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Dispense in a tight, child-resistant container as defined in the USP/NF. PROTECT FROM MOISTURE.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet or capsule or lithium citrate products \n       \n \n  [see Adverse Reactions (\n        \n  \n   6)]."
}